These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17237831)

  • 1. Measure for measure--sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy.
    Rosenson RS
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):72-3. PubMed ID: 17237831
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
    März W
    MMW Fortschr Med; 2005 Apr; 147(14):14. PubMed ID: 15887675
    [No Abstract]   [Full Text] [Related]  

  • 3. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiologist's role in improving glucose control and global cardiovascular risk in patients with type 2 diabetes mellitus.
    Gotto AM
    Am J Cardiol; 2007 Feb; 99(4A):3B-5B. PubMed ID: 17307053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J
    Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The case for lipid control.
    Lipold AG
    Bus Health; 2001 Dec; 19(12 Suppl A):12-5. PubMed ID: 11799636
    [No Abstract]   [Full Text] [Related]  

  • 7. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract]   [Full Text] [Related]  

  • 8. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.
    Cannon CP
    Am J Cardiol; 2008 Dec; 102(12A):5L-9L. PubMed ID: 19084083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma lipoproteins as cardiovascular risk factors in diabetes.
    Manzato E
    Aging (Milano); 1998 Apr; 10(2):169-70. PubMed ID: 9666226
    [No Abstract]   [Full Text] [Related]  

  • 11. [Diabetic dyslipidemia: which target levels and treatment options exist for diabetics?].
    Broedl UC; Lehrke M; Parhofer KG
    MMW Fortschr Med; 2008 Jun; 150(25):41-3. PubMed ID: 18705054
    [No Abstract]   [Full Text] [Related]  

  • 12. New insights into understanding cardiometabolic risk. Introduction.
    Fonarow GC; Watson KE
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S1-2. PubMed ID: 17934389
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease.
    Rana JS; Nieuwdorp M; Jukema JW; Kastelein JJ
    Diabetes Obes Metab; 2007 May; 9(3):218-32. PubMed ID: 17391148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The metabolic syndrome threatens public health. Increased physical activity the best cure].
    Hellénius ML; Rauramaa R
    Lakartidningen; 2007 Dec; 104(51-52):3857-61. PubMed ID: 18232526
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination therapy in the management of mixed dyslipidaemia.
    Cannon CP
    J Intern Med; 2008 Apr; 263(4):353-65. PubMed ID: 18324928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. I read that nearly a quarter of adult Americans have "metabolic syndrome". What is this malady, and how can I prevent it?
    Blackburn GL
    Health News; 2002 Nov; 8(11):12. PubMed ID: 12523258
    [No Abstract]   [Full Text] [Related]  

  • 17. Obesity and metabolic disease.
    Koopman RJ; Swofford SJ; Beard MN; Meadows SE
    Prim Care; 2009 Jun; 36(2):257-70. PubMed ID: 19501242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.
    Brunzell JD; Davidson M; Furberg CD; Goldberg RB; Howard BV; Stein JH; Witztum JL; ;
    Diabetes Care; 2008 Apr; 31(4):811-22. PubMed ID: 18375431
    [No Abstract]   [Full Text] [Related]  

  • 19. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M
    Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy and clinical trials.
    Usman M; Peter R
    Curr Opin Lipidol; 2006 Oct; 17(5):612-4. PubMed ID: 16960511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.